13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001560009
Total reported value
$162.6M
$162.6M
7 檔
91.5%
At the close of Q4 2025, Versant Venture Management, LLC disclosed equity holdings valued at approximately $162.6M, spread across 7 reported holdings.
In Q4 2025, Versant Venture Management, LLC adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 2 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 45.49% | +10.34% | -22.47% | |
| 2 | LENZ | Lenz Therapeutics Inc | Stock-Other | 28.14% | -7.91% | — | |
| 3 | JBIO | Jade Biosciences Inc | Stock-Other | 15.59% | -1.61% | — | |
| 4 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 5.17% | -0.02% | — | |
| 5 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 4.11% | +0.46% | — | |
| 6 | SKYE | Skye Bioscience Inc | Stock-Other | 1.00% | -0.01% | — | |
| 7 | OVASUSD | Tempest Therapeutics Inc | Stock-Other | 0.51% | -0.13% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GLUE | Monte Rosa Therapeutics Inc | +25.8% | -22.47% | Trim |
| 2 | JBIO | Jade Biosciences Inc | +9.4% | — | Unchanged |
| 3 | CTNM | Contineum Therapeutics Inc-a | +1.1% | — | Unchanged |
| 4 | CRSP | CRISPR Therapeutics AG | +0.6% | — | Unchanged |
| 5 | OVASUSD | Tempest Therapeutics Inc | -0.8% | — | Unchanged |
| 6 | SKYE | Skye Bioscience Inc | -2.7% | — | Unchanged |
| 7 | LENZ | Lenz Therapeutics Inc | -30.1% | — | Unchanged |
| 8 | RPTX | Repare Therapeutics Inc | — | EXIT | Sold out |
| 9 | ADVMCHF | Adverum Biotechnologies Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Versant Venture Management, LLC reported a total U.S. public equity portfolio value of $162.6M across 7 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including GLUE, LENZ, JBIO) accounted for 91.5% of total reported equity market value during Q4 2025.
Top Position Liquidated / Trimmed
RPTX
前期市值: $4.7M
During Q4 2025, Versant Venture Management, LLC's top holdings by market value included GLUE (45.5%)、LENZ (28.1%)、JBIO (15.6%). The largest single position, GLUE, represented 45.5% of total portfolio value.
In Q4 2025, Versant Venture Management, LLC made 3 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 1 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.